Adaptive Biotechnologies
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $47,459 | $46,435 | $43,190 | $41,873 |
Gross Profit | 29,414 | 29,768 | 21,088 | 23,822 |
EBITDA | -26,317 | -24,567 | -38,549 | -39,326 |
EBIT | -30,765 | -29,158 | -43,552 | -44,540 |
Net Income | -33,692 | -32,071 | -46,222 | -47,507 |
Net Change In Cash | 47,459 | 46,435 | 43,190 | 41,873 |
Free Cash Flow | -12,571 | -27,409 | -19,032 | -39,864 |
Cash | 47,920 | 38,084 | 59,824 | 71,233 |
Basic Shares | 147,101 | 147,516 | 147,414 | 145,787 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $178,957 | $170,276 | $185,308 | $154,344 |
Gross Profit | 106,877 | 94,723 | 127,399 | 105,043 |
EBITDA | -128,759 | -189,273 | -167,983 | -193,345 |
EBIT | -148,015 | -211,504 | -196,130 | -214,326 |
Net Income | -159,492 | -225,250 | -142,464 | -205,611 |
Net Change In Cash | 178,957 | 170,276 | 185,308 | 154,344 |
Cost of Revenue | -48,775 | 15,629 | ||
Free Cash Flow | -98,876 | -167,021 | -200,294 | -254,473 |
Cash | 47,920 | 65,063 | 90,030 | 139,065 |
Basic Shares | 147,101 | 144,383 | 142,515 | 140,354 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.22 |
2024-09-30 | -$0.22 |
2024-06-30 | -$0.31 |
2024-03-31 | -$0.33 |
